Silexion Therapeutics (SLXN) vs. The Competition Head to Head Contrast

Silexion Therapeutics (NASDAQ:SLXN) is one of 618 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its rivals? We will compare Silexion Therapeutics to related companies based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, risk and analyst recommendations.

Valuation and Earnings

This table compares Silexion Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Silexion Therapeutics	N/A	-$16.44 million	-0.01
Silexion Therapeutics Competitors	$960.32 million	-$45.54 million	14.46

Silexion Therapeutics’ rivals have higher revenue, but lower earnings than Silexion Therapeutics. Silexion Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Silexion Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	N/A	-355.74%
Silexion Therapeutics Competitors	-1,434.00%	-642.77%	-28.21%

Volatility & Risk

Silexion Therapeutics has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Silexion Therapeutics’ rivals have a beta of 0.97, suggesting that their average share price is 3% less volatile than the S&P 500.

Insider & Institutional Ownership

10.9% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 6.0% of Silexion Therapeutics shares are owned by insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Silexion Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1	0	1	0	2.00
Silexion Therapeutics Competitors	5312	11927	37153	1117	2.61

Silexion Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 2,400.00%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 66.89%. Given Silexion Therapeutics’ higher possible upside, equities research analysts clearly believe Silexion Therapeutics is more favorable than its rivals.

Summary

Silexion Therapeutics rivals beat Silexion Therapeutics on 9 of the 13 factors compared.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.